Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B.
Arch Virol
; 167(8): 1669-1674, 2022 Aug.
Article
en En
| MEDLINE
| ID: mdl-35598207
ABSTRACT
The aim of this study was to evaluate plasmatic and urinary therapeutic drug monitoring (TDM) of tenofovir disoproxil fumarate (TDF) in a cohort of patients with chronic hepatitis B (CHB). In 68 enrolled patients, the estimated glomerular filtration rate (eGFR) was 68 mL/min in naive subjects, while in adefovir dipivoxil (ADV)-pretreated patients, it was 55.5 mL/min (p < 0.001). The HBV E genotype was associated with lower TDF levels (ß = -0.698, p < 0.001). The urinary TDF concentration was associated with ADV pretreatment (ß = 0.829, p < 0.001). Determination of urinary concentrations of TDF may be useful in the clinical management of older CHB patients and those with previous treatment with ADV.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Hepatitis B Crónica
Tipo de estudio:
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Arch Virol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Italia